| Biological Information | |
|---|---|
| Background Information: | N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the Q252H mutation. The Abl tyrosine kinase inhibitor STI571 is an effective therapy for stable-phase chronic myeloid leukemia patients. Many patients responding to STI571 later relapse due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the Q252H mutation, which confers resistance to drug binding (Shah et al., (2002), Cancer Cell 2, 117-125). |
| Target Class: | Kinase |
| Accession Number: | NM_005157.3; NM_007313.2 |
| Target Name: | Abl |
| Target Aliases: | ABL1, JTK7, p150, bcr/abl, v-abl, c-ABL, ABL |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 6 months at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
Abl (Q252H), active
10 µg of active Abl (Q252H). N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end containing the Q252H mutation.
Datasheets
14-751x Datasheet
View Document